Abstract 284
Background
In the United States, the incidence of developing colorectal cancer is < 5% in both males and females. The 5-year survival rates in stage IIA and IIB are 87% and 63% respectively. Surgery is the definitive treatment of stage II, while adding chemotherapy is still a debate. So we conducted this study to evaluate the efficacy of combined surgery and chemotherapy in the 5-year survival rates of stage II colorectal adenocarcinoma.
Methods
The data of 1231 patients with colorectal adenocarcinoma stage II from 2010 were collected using SEER database. There were 502 (41%) patients had combined chemotherapy and surgery, while 729 (59%) of them had surgery only. Patients’ demographics, carcinoembryonic antigen (CEA) test results, primary sites and sub stages of tumor were assessed.
Results
Patients with stage II colorectal adenocarcinoma who received combined surgery and chemotherapy had better 5-year relative survival rates (89%) than who went under surgery only (84.6%), (p-value <0.001). 5-year relative survival rates of combination were better in females (90.8%), negative CEA patients (93.4%), patients aged 20-40 years (100) and stage IIA (92.1%), (p-value <0.05). race and primary site of tumor were insignificant prognostic factors.
Table: 91P
Variables | Survival of Patients | p value |
---|---|---|
CEA (carcinoembryonicantigen) positive Negative | 81.9% 93.4% | <0.05* |
Sex Male Female | 87.3 % 90.8% | <0.05* |
Age 20- 40 41- 60 61- 80 >80 | 100% 90.5% 87.9% 46.5% | <0.0001** |
Race White Black Others | 89.2% 79.9% 92.6% | 0.261 |
Primary Site Ceacum Ascending colon Transverse colon Splenic flexure Descending colon Sigmoid colon Rectosigmoid junction Rectum | 74.5% 88% 91.9% 100% 89.8% 92.4% 86.8% 88.5% | 0.661 |
Stage IIA IIB IIC | 92.1% 76.2% 63.4% | <0.0001** |
Highly significant P-value ≤ 0.001
*significant P-value <0.05
Conclusions
combined surgery and chemotherapy have better 5-year survival rates compared with surgery alone especially in those who are females, or have negative CEA test, aged 20-40 years or at stage IIA colorectal adenocarcinoma.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Faculty of Medicine Suez Canal University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
750 - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst 1,095 consecutive Asian patients
Presenter: Ga Jing Kee
Session: Poster display - Cocktail
Resources:
Abstract
1417 - CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and accurate solution for Asia
Presenter: Manjiri Bakre
Session: Poster display - Cocktail
Resources:
Abstract
1468 - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial
Presenter: Sepideh Elyasi
Session: Poster display - Cocktail
Resources:
Abstract
873 - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery
Presenter: Kannan Periasamy
Session: Poster display - Cocktail
Resources:
Abstract
1140 - Triple Negative Breast Cancer and Platinum-based Systemic Treatment: Meta-analysis and Systematic Review
Presenter: Jessa Gilda Pandy
Session: Poster display - Cocktail
Resources:
Abstract
168 - Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer
Presenter: Winnie Yeo
Session: Poster display - Cocktail
Resources:
Abstract
311 - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay
Presenter: Hanjing Xie
Session: Poster display - Cocktail
Resources:
Abstract
669 - A novel nipple aleolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer
Presenter: Hirohito Seki
Session: Poster display - Cocktail
Resources:
Abstract
938 - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer
Presenter: Tae Hyun Kim
Session: Poster display - Cocktail
Resources:
Abstract
1129 - Implication of PET-CT to improve negative predictive value for axillary lymph node metastasis in early breast cancer
Presenter: Oyeon Cho
Session: Poster display - Cocktail
Resources:
Abstract